P. Sukrakanchana

Intensive pharmacokinetics of zidovudine 200 mg twice daily in HIV-1-infected patients weighing less than 60 kg on highly active antiretroviral therapy.

T. Cressey, M. Lallemant, Yardpiroon Tawon, 2006, Journal of acquired immune deficiency syndromes.

Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network

P. Musoke, ASM Nawshad Uddin Ahmed, S. Lochindarat, 2019, Archives of Disease in Childhood.

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Ana C. Matos, C. Königs, J. Seeley, 2022, The lancet. HIV.

Challenges in the Implementation of the NeoOBS Study, a Global Pragmatic Observational Cohort Study, to Investigate the Aetiology and Management of Neonatal Sepsis in the Hospital Setting

S. Lochindarat, J. Bielicki, B. Adhisivam, 2023, Antibiotics.

Plasma Pharmacokinetics and Urinary Excretion of Tenofovir Following Cessation in Adults with Controlled Levels of Adherence to Tenofovir Disoproxil Fumarate.

J. Baeten, P. Drain, M. Gandhi, 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

confUrine Tenofovir Concentrations Correlate with Plasma and Relates to TDF Adherence: A Randomized Directly-observed Pharmacokinetic Trial (TARGET Study).

J. Baeten, P. Drain, P. Bacchetti, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study

J. Baeten, P. Drain, J. Quame-Amaglo, 2017, BMC Infectious Diseases.

Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.

C. Fletcher, A. Avihingsanon, V. Klinbuayaem, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Ana C. Matos, C. Königs, C. Giaquinto, 2022, The lancet. HIV.

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinic

J. Blackstone, E. Williams, C. Giaquinto, 2023, EClinicalMedicine.

Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates

L. Aarons, S. Urien, E. Capparelli, 2017, Journal of acquired immune deficiency syndromes.

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

J. Seeley, C. Giaquinto, O. Kobusingye, 2021, BMC Infectious Diseases.